Search
Spotlight
Bench to Bedside With SIDP
C difficile
COVID Vaccine Race
The COVID-19 Live Vaccine Tracker
Clinical
Coronavirus
Blood-Borne Diseases
Food-Borne Infections
Gastrointestinal Infections
Healthcare-Associated Infections
Prevention
Respiratory Diseases
Sexually Transmitted Diseases
Skin & Soft Tissue Diseases
Zoonotic & Vector-Borne Diseases
Video Series
Insights
Peer Exchange
Peers and Perspectives
Media
Medical World News
News Articles
Podcasts
Videos
Conference
Conference Coverage
Conference Listing
Publications
Resources
Continuing Education
Interactive Tools
Partners
Special Projects
Subscribe
Search
Spotlight
Bench to Bedside With SIDP
C difficile
COVID Vaccine Race
The COVID-19 Live Vaccine Tracker
Clinical
See All >
Coronavirus
Blood-Borne Diseases
Food-Borne Infections
Gastrointestinal Infections
Healthcare-Associated Infections
Prevention
Respiratory Diseases
Sexually Transmitted Diseases
Skin & Soft Tissue Diseases
Zoonotic & Vector-Borne Diseases
Video Series
Insights
Peer Exchange
Peers and Perspectives
Peer Exchange
All Topics
ANTIBIOTICS
BLOOD-BORNE DISEASES
C. DIFFICILE
GASTROINTESTINAL INFECTIONS
HEALTHCARE-ASSOCIATED INFECTIONS (HAI)
HIV / AIDS
LYME DISEASE
MRSA
PREVENTION
PrEP
RESPIRATORY INFECTIONS
SEXUALLY TRANSMITTED DISEASES
SKIN & SOFT TISSUE DISEASES
VACCINES
ZOONOTIC & VECTOR-BORNE DISEASES
Apply
Expert Perspectives on Advances in the Management of C. difficile
EP. 1:
C. Difficile Risk Factors and Manifestation
EP. 1:
C. Difficile Risk Factors and Manifestation
EP. 2:
Strains of C. Difficile
EP. 2:
Strains of C. Difficile
EP. 3:
Managing Community-Onset C. Difficile
EP. 3:
Managing Community-Onset C. Difficile
EP. 4:
Recurrent C. Difficile
EP. 4:
Recurrent C. Difficile
EP. 5:
C. Difficile: A Differential Diagnosis
EP. 5:
C. Difficile: A Differential Diagnosis
EP. 6:
Testing for C. Difficile Infections
EP. 6:
Testing for C. Difficile Infections
EP. 7:
Screening for C. Difficile
EP. 7:
Screening for C. Difficile
EP. 8:
C. Difficile: Clinical Practice Guidelines and Treatment Options
EP. 8:
C. Difficile: Clinical Practice Guidelines and Treatment Options
EP. 9:
C. Difficile: Updates to Clinical Practice Guidelines
EP. 9:
C. Difficile: Updates to Clinical Practice Guidelines
EP. 10:
Selecting Therapy to Treat C. Difficile
EP. 10:
Selecting Therapy to Treat C. Difficile
EP. 11:
C. Difficile Treatment: Fidaxomicin
EP. 11:
C. Difficile Treatment: Fidaxomicin
EP. 12:
Choosing Between Vancomycin and Fidaxomicin for C. Difficile Infections
EP. 12:
Choosing Between Vancomycin and Fidaxomicin for C. Difficile Infections
EP. 13:
C. Difficile Treatment: Bezlotoxumab
EP. 13:
C. Difficile Treatment: Bezlotoxumab
EP. 14:
Preventing/Treating C. Difficile: Unmet Needs
EP. 14:
Preventing/Treating C. Difficile: Unmet Needs
EP. 15:
Fecal Microbiota Transplantation for C. Difficile Infections
EP. 15:
Fecal Microbiota Transplantation for C. Difficile Infections
EP. 16:
Emerging Treatment Options for C. Difficile Infections
EP. 16:
Emerging Treatment Options for C. Difficile Infections
EP. 17:
C. Difficile: Barriers Treating With FMT
EP. 17:
C. Difficile: Barriers Treating With FMT
EP. 18:
Making Strides in the Management of C. Difficile
EP. 18:
Making Strides in the Management of C. Difficile
Advances in the Treatment Landscape for HIV
EP. 1:
Burden of HIV in the USA and Associated Symptoms
EP. 1:
Burden of HIV in the USA and Associated Symptoms
EP. 2:
Screening Recommendations for HIV and Risk Stratification
EP. 2:
Screening Recommendations for HIV and Risk Stratification
EP. 3:
PrEP Therapy for High-Risk HIV Candidates
EP. 3:
PrEP Therapy for High-Risk HIV Candidates
EP. 4:
Safety Profiles of FDA-Approved PrEP Agents
EP. 4:
Safety Profiles of FDA-Approved PrEP Agents
EP. 5:
State Medicaid Reimbursement for Routine HIV Screening
EP. 5:
State Medicaid Reimbursement for Routine HIV Screening
EP. 6:
Rapid Initiation of HIV Treatment With ART
EP. 6:
Rapid Initiation of HIV Treatment With ART
EP. 7:
Factors Considered in Choosing Initial HIV Therapeutic Regimen
EP. 7:
Factors Considered in Choosing Initial HIV Therapeutic Regimen
EP. 8:
Safety Profile and Costs of Initial HIV Therapeutic Regimen
EP. 8:
Safety Profile and Costs of Initial HIV Therapeutic Regimen
EP. 9:
Switching Therapies in Patients Who Are Successfully Treated
EP. 9:
Switching Therapies in Patients Who Are Successfully Treated
EP. 10:
Virological Failure or Rebound to HIV Therapies
EP. 10:
Virological Failure or Rebound to HIV Therapies
EP. 11:
Emerging Treatment Options for HIV
EP. 11:
Emerging Treatment Options for HIV
EP. 12:
Drug Resistance or Intolerance to HIV Therapy
EP. 12:
Drug Resistance or Intolerance to HIV Therapy
EP. 13:
Long-Acting Injectables to Treat HIV
EP. 13:
Long-Acting Injectables to Treat HIV
EP. 14:
Long-Acting Injectables as PrEP Therapy
EP. 14:
Long-Acting Injectables as PrEP Therapy
HIV Screening, Prevention, and Treatment Advances
EP. 1:
The HIV Treatment Landscape
EP. 1:
The HIV Treatment Landscape
EP. 2:
HIV Screening and Diagnosis
EP. 2:
HIV Screening and Diagnosis
EP. 3:
HIV Pre-Exposure Prophylaxis Therapy
EP. 3:
HIV Pre-Exposure Prophylaxis Therapy
EP. 4:
HIV Treatment: Initiation, Adherence, and Accessibility
EP. 4:
HIV Treatment: Initiation, Adherence, and Accessibility
EP. 5:
HIV US Preventive Task Force Screening Recommendations
EP. 5:
HIV US Preventive Task Force Screening Recommendations
EP. 6:
HIV: Undetectable Equals Untransmittable
EP. 6:
HIV: Undetectable Equals Untransmittable
EP. 7:
HIV Therapy Selection for the General Population
EP. 7:
HIV Therapy Selection for the General Population
EP. 8:
HHS vs IAS-USA Guidelines for HIV
EP. 8:
HHS vs IAS-USA Guidelines for HIV
EP. 9:
HIV Treatment Options for Pregnant Women
EP. 9:
HIV Treatment Options for Pregnant Women
EP. 10:
Dolutegravir + Rilpivirine Combination Therapy for HIV
EP. 10:
Dolutegravir + Rilpivirine Combination Therapy for HIV
EP. 11:
The Difficulty of Switching ART Regimens in HIV
EP. 11:
The Difficulty of Switching ART Regimens in HIV
EP. 12:
Recommended HIV-Monitoring Approach for Stable Patients
EP. 12:
Recommended HIV-Monitoring Approach for Stable Patients
EP. 13:
Virological Failure and Incomplete Response in HIV
EP. 13:
Virological Failure and Incomplete Response in HIV
EP. 14:
Significance of Low-Level Viremia Indication in HIV
EP. 14:
Significance of Low-Level Viremia Indication in HIV
EP. 15:
HIV Long-Acting Injectable Therapies in Development
EP. 15:
HIV Long-Acting Injectable Therapies in Development
EP. 16:
HIV Noninjectable Long-Acting Therapies in Development
EP. 16:
HIV Noninjectable Long-Acting Therapies in Development
Outpatient Management of Acute Bacterial Skin and Skin Structure Infections
EP. 1:
An Overview of ABSSSI
EP. 1:
An Overview of ABSSSI
EP. 2:
Understanding the Prevalence of ABSSSI in the Community
EP. 2:
Understanding the Prevalence of ABSSSI in the Community
EP. 3:
ABSSSI: Standard Protocol of Admission and Treatment
EP. 3:
ABSSSI: Standard Protocol of Admission and Treatment
EP. 4:
Cost Considerations of IV Antibiotics for ABSSSI
EP. 4:
Cost Considerations of IV Antibiotics for ABSSSI
EP. 5:
Oral Antibiotic Compliance for ABSSSI
EP. 5:
Oral Antibiotic Compliance for ABSSSI
EP. 6:
Treatment of ABSSSI: Inpatient Versus Outpatient
EP. 6:
Treatment of ABSSSI: Inpatient Versus Outpatient
EP. 7:
ABSSSI: Outpatient Parenteral Antibiotic Therapy
EP. 7:
ABSSSI: Outpatient Parenteral Antibiotic Therapy
EP. 8:
Determining the Severity of ABSSSI
EP. 8:
Determining the Severity of ABSSSI
EP. 9:
Lipoglycopeptide Therapies for Gram-Positive Infections
EP. 9:
Lipoglycopeptide Therapies for Gram-Positive Infections
EP. 10:
Gram-Positive ABSSSI: Early Identification and Follow-Up
EP. 10:
Gram-Positive ABSSSI: Early Identification and Follow-Up
EP. 11:
ABSSSI Case Scenarios for OPAT
EP. 11:
ABSSSI Case Scenarios for OPAT
EP. 12:
Trends of ABSSSI Incidence in the Community
EP. 12:
Trends of ABSSSI Incidence in the Community
EP. 13:
Establishing Real-World Protocols for OPAT
EP. 13:
Establishing Real-World Protocols for OPAT
EP. 14:
OPAT Protocols: Navigating Challenges
EP. 14:
OPAT Protocols: Navigating Challenges
EP. 15:
Lipoglycopeptide Antibiotics for ABSSSI: Education
EP. 15:
Lipoglycopeptide Antibiotics for ABSSSI: Education
EP. 16:
Standard Protocol for the Treatment of ABSSSI
EP. 16:
Standard Protocol for the Treatment of ABSSSI
EP. 17:
Cost Considerations for the Treatment of ABSSSI
EP. 17:
Cost Considerations for the Treatment of ABSSSI
EP. 18:
Risk Stratification for ABSSSI
EP. 18:
Risk Stratification for ABSSSI
EP. 19:
Long-Acting Lipoglycopeptide Antibiotics for ABSSSI
EP. 19:
Long-Acting Lipoglycopeptide Antibiotics for ABSSSI
EP. 20:
Establishing a Protocol for OPAT
EP. 20:
Establishing a Protocol for OPAT
EP. 21:
Future of OPAT for ABSSSI
EP. 21:
Future of OPAT for ABSSSI
Battling Against Resistant Pseudomonas Infections in the ICU
EP. 1:
<i>Pseudomonas</i> Infections in the ICU: Who's Susceptible?
EP. 1:
<i>Pseudomonas</i> Infections in the ICU: Who's Susceptible?
EP. 2:
<i>Pseudomonas</i> Infections: Matching Causes and Prevention
EP. 2:
<i>Pseudomonas</i> Infections: Matching Causes and Prevention
EP. 3:
<i>Pseudomonas</i> Infections in the ICU Versus on the Floor
EP. 3:
<i>Pseudomonas</i> Infections in the ICU Versus on the Floor
EP. 4:
<i>Pseudomonas</i> Infections: Nuancing the Use of Antibiotics
EP. 4:
<i>Pseudomonas</i> Infections: Nuancing the Use of Antibiotics
EP. 5:
Fighting <i>Pseudomonas</i>: Impact On Patient Prognosis & Approaches to Combat Infection
EP. 5:
Fighting <i>Pseudomonas</i>: Impact On Patient Prognosis & Approaches to Combat Infection
EP. 6:
Classes and Agents Available to Treat <i>Pseudomonas</i> Infections
EP. 6:
Classes and Agents Available to Treat <i>Pseudomonas</i> Infections
EP. 7:
<i>Pseudomonas</i> Infections Continue to Acquire Resistance, Complicating Treatment
EP. 7:
<i>Pseudomonas</i> Infections Continue to Acquire Resistance, Complicating Treatment
EP. 8:
Exploring Cephalosporin/β-Lactamase Inhibitor Combinations for Treatment of <i>Pseudomonas</i>
EP. 8:
Exploring Cephalosporin/β-Lactamase Inhibitor Combinations for Treatment of <i>Pseudomonas</i>
EP. 9:
Exploring Appropriate Treatment Protocols for <i>Pseudomonas</i> Infections
EP. 9:
Exploring Appropriate Treatment Protocols for <i>Pseudomonas</i> Infections
EP. 10:
Core Challenges in <i>Pseudomonas</i> Treatment Protocol
EP. 10:
Core Challenges in <i>Pseudomonas</i> Treatment Protocol
EP. 11:
<i>Pseudomonas</i> Infections: Optimizing Diagnostic Strategies
EP. 11:
<i>Pseudomonas</i> Infections: Optimizing Diagnostic Strategies
EP. 12:
Pseudomonas Infections: Selecting Upfront Antibiotics
EP. 12:
Pseudomonas Infections: Selecting Upfront Antibiotics
EP. 13:
<i>Pseudomonas</i> Infections: Secondary Approach to Treatment
EP. 13:
<i>Pseudomonas</i> Infections: Secondary Approach to Treatment
EP. 14:
Treating <i>Pseudomonas</i> Infections With Zerbaxa or Avycaz
EP. 14:
Treating <i>Pseudomonas</i> Infections With Zerbaxa or Avycaz
EP. 15:
Zerbaxa and Avycaz: Considerations for Treatment
EP. 15:
Zerbaxa and Avycaz: Considerations for Treatment
EP. 16:
The Future Treatment of Pseudomonas Infections
EP. 16:
The Future Treatment of Pseudomonas Infections
Outsmarting Resistant Infections
EP. 1:
An Overview of Multidrug-Resistant Bacterial Infections
EP. 1:
An Overview of Multidrug-Resistant Bacterial Infections
EP. 2:
Understanding the Causes and Impact of MDR Infections
EP. 2:
Understanding the Causes and Impact of MDR Infections
EP. 3:
MDR Infections: Current Pathogen and Treatment Paradigm
EP. 3:
MDR Infections: Current Pathogen and Treatment Paradigm
EP. 4:
Gram-Negative Nosocomial Infections: Systemic Risk
EP. 4:
Gram-Negative Nosocomial Infections: Systemic Risk
EP. 5:
Factors in Choosing Therapy for Gram-Negative NIs
EP. 5:
Factors in Choosing Therapy for Gram-Negative NIs
EP. 6:
Diagnostic Tests for Gram-Negative Nosocomial Infections
EP. 6:
Diagnostic Tests for Gram-Negative Nosocomial Infections
EP. 7:
Gram-Negative NIs: Vabomere and the TANGO II Study
EP. 7:
Gram-Negative NIs: Vabomere and the TANGO II Study
EP. 8:
Gram-Negative NIs: Cephalosporin/β-Lactamase Inhibitors
EP. 8:
Gram-Negative NIs: Cephalosporin/β-Lactamase Inhibitors
EP. 9:
Understanding Gram-Positive Nosocomial Infections
EP. 9:
Understanding Gram-Positive Nosocomial Infections
EP. 10:
Selecting Lipoglycopeptide Therapy for Gram-Positive NIs
EP. 10:
Selecting Lipoglycopeptide Therapy for Gram-Positive NIs
EP. 11:
Gram-Positive NIs: Nuancing Lipoglycopeptide Therapy
EP. 11:
Gram-Positive NIs: Nuancing Lipoglycopeptide Therapy
EP. 12:
Gram-Positive NIs: Costs of Lipoglycopeptide Therapy
EP. 12:
Gram-Positive NIs: Costs of Lipoglycopeptide Therapy
EP. 13:
MDR Infections: Overview of Antimicrobial Stewardships
EP. 13:
MDR Infections: Overview of Antimicrobial Stewardships
EP. 14:
Importance of Technology & Data Within Antibiotic Stewardship Programs
EP. 14:
Importance of Technology & Data Within Antibiotic Stewardship Programs
EP. 15:
Antimicrobial Stewardship Programs: Goals and Challenges
EP. 15:
Antimicrobial Stewardship Programs: Goals and Challenges
EP. 16:
Multidrug-Resistant Bacterial Infections: Key Messages
EP. 16:
Multidrug-Resistant Bacterial Infections: Key Messages